| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T23348 | ||||
| Target Name | von Willebrand factor (VWF) | ||||
| Type of Target |
Successful |
||||
| Action against Disease Model | ALX-0081 | Drug Info | ALX-0081 exerts potent activity in vitro and in vivo. Perfusion experiments with blood from patients with acute coronary syndrome on standard antithrombotics demonstrated complete inhibition of platelet adhesion after addition of ALX-0081, while in the absence of ALX-0081 residual adhesion was observed. In a baboon efficacy and safety model measuring acute thrombosis and surgical bleeding, ALX-0081 showed a superior therapeutic window compared to marketed antithrombotics. | [1] | |
| References | |||||
| REF 1 | Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011 Jul 21;118(3):757-65. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.